Phospholipid-dependent interaction between dibromothymoquinone and iron-sulfur protein in mitochondrial ubiquinol-cytochrome c reductase.
Dibromothymoquinone (DBMIB) inhibits antimycin A-sensitive ubiquinol-cytochrome c reductase activity; the maximal inhibition is 90%. DBMIB alters the EPR spectra of reduced iron-sulfur protein in intact ubiquinol-cytochrome c reductase. The maximal spectral change occurs with 60 mol inhibitor per mol cytochrome c1 in the reductase. DBMIB causes little alteration in the EPR characteristics of iron-sulfur protein when ubiquinol-cytochrome c reductase is delipidated. When delipidated ubiquinol-cytochrome c reductase is replenished with phospholipid, the effect of DBMIB reappears. However, when DBMIB is added to delipidated protein prior to replenishment with phospholipid, very little spectral alteration is observed. DBMIB does not alter the EPR spectra of purified iron-sulfur protein, with or without phospholipid in the preparation. Reduced DBMIB does not alter the EPR characteristics of iron-sulfur protein in intact or delipidated ubiquinol-cytochrome c reductase. Cysteine and other thiol compounds can reverse the spectral alternation caused by DBMIB. This reversal probably results from the reduction of DBMIB.
D000818:Animals; D000968:Antimycin A / Q000494:pharmacology; D002417:Cattle; D003991:Dibromothymoquinone / Q000494:pharmacology*; D004578:Electron Spin Resonance Spectroscopy; D014450:Electron Transport Complex III / Q000378:metabolism*; D007506:Iron-Sulfur Proteins / Q000378:metabolism*; D007700:Kinetics; D008667:Metalloproteins / Q000378:metabolism*; D008929:Mitochondria, Heart / Q000201:enzymology*; D010743:Phospholipids / Q000494:pharmacology*; D011809:Quinones / Q000494:pharmacology*
D007506:Iron-Sulfur Proteins; D008667:Metalloproteins; D010743:Phospholipids; D011809:Quinones; D003991:Dibromothymoquinone; D000968:Antimycin A; D014450:Electron Transport Complex III